

November 11, 2024

Listing Department BSE LIMITED P. J. Towers, Dalal Street, <u>Mumbai–400 001</u> Code: 531 335

Listing Department **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), <u>Mumbai–400 051</u> Code: ZYDUSWELL

Sub: Outcome of Board Meeting

Ref.: Unaudited financial results for the quarter and half year ended on September 30, 2024 pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")

Dear Sir / Madam,

The Board of Directors at their meeting held today i.e. November 11, 2024, based on the recommendations of Audit Committee, approved the unaudited financial results for the quarter and half year ended on September 30, 2024.

In this regard, please find enclosed the following:

- the unaudited financial results (standalone and consolidated) for the quarter and half year ended on September 30, 2024, reviewed by the Audit Committee and taken on record by the Board of Directors, today i.e. November 11, 2024 pursuant to regulation 33 of the Listing Regulations.
- 2. the Limited Review Reports of Mukesh M. Shah & Co., Chartered Accountants and the Statutory Auditors of the Company certifying the limited review of the unaudited financial

Zydus Wellness Limited

Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India. Phone No.: +91-79-71800000; Website: <u>www.zyduswellness.com</u> CIN: L15201GJ1994PLC023490



results (standalone and consolidated) of the Company for the quarter and half year ended on September 30, 2024 pursuant to regulation 33 of the Listing Regulations.

The Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed until Wednesday, November 13, 2024 and shall re-open for trading for all Directors and Designated Persons on and from Thursday, November 14, 2024.

The Board meeting commenced at 10:45 a.m. and concluded at 12:00 noon.

Please find the same in order.

Thanking you,

Yours faithfully, For, **ZYDUS WELLNESS LIMITED**

NANDISH P. JOSHI COMPANY SECRETARY

Encl.: As above

Zydus Wellness Limited Regd. Office: 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad – 382481, India. Phone No.: +91-79-71800000; Website: <u>www.zyduswellness.com</u> CIN: L15201GJ1994PLC023490

MUKESH M. SHAH & CO.

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

То,
The Board of Directors,
Zydus Wellness Limited

- We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Zydus Wellness Limited ['the Company'], for the quarter and half year ended on September 30, 2024 ['the Statement'] attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
- 2. This statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

SH M. SH4// 7. Heritage Chambers, Nehru Nagas, Ambaveal Ambaveal

For Mukesh M. Shah & Co **Chartered Accountants** Firm Registration No. 106625W

Mukesh M. Shah Partner Membership No. 030190

Place: Ahmedabad Date: November 11, 2024 UDIN: 240301908KHRYH7785

+91-79-26472000 | contact@mmsco.in | www.mmsco.in

^{7&}lt;sup>th</sup> Floor, Herit age Chambers, Behind Bikanerwala Sweets, Near Azad Society, Nehru Nagar, Ahmedabad-380015

Prest		s Wellness Lir					
Zyd	Jense Andread A			ninagar), Near Vai	shnodevi Circle,		
Alellir	1255 Sarkhej-Gandhina	agar Highway, Ahm	edabad 382 481.				
	Tel. No. (+91-79) 4804 0000 Website:						
	Statement of Standalone Unaudited Financial Re	esults for the Q	uarter and Hal	f year ended S	eptember 30,	2024	
		Landan and a second		₹in M	lillion		
	- X		Quarter Ended		Half Yea	r Ended	Year Ended
		September	June	September	September	September	March
Sr. No.	Particulars	30, 2024	30, 2024	30, 2023	30, 2024	30, 2023	31, 2024
		[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Audited]
1	Income						
а	Revenue from operations						
i	Sales	532	544	496	1,076	1,012	2,0
ii	Other operating income	101	90	82	191	167	3
	Total Revenue from operations	633	634	578	1,267	1,179	2,4
b	Other income	41	48	46	89	87	1
	Total Income	674	682	624	1,356	1,266	2,6
2	Expenses						
а	Cost of materials consumed	412	401	368	813	750	1,5
b	Changes in inventories of finished goods and work-in-progress	(5)	(4)	(1)	(9)	4	
С	Employee benefits expense	88	111	81	199	157	2
d	Finance costs	2	8	8	10	8	
e	Depreciation and amortisation expense	9	9	9	18	18	5
f	Other expenses	63	73	56	136	122	2
g	Net gain on foreign currency transactions	-	-	(1)	-	(1)	
	Total Expenses	569	598	520	1,167	1,058	2,1
3	Profit before tax [1-2]	105	84	104	189	208	4
4	Tax expense						
а	Current tax	-	1		1	(2)	
b	Deferred tax	25	21	26	46	50	1
	Total tax expense	25	22	26	47	48	1
5	Net Profit [3-4]	80	62	78	142	160	5
6	Other Comprehensive Income [OCI]						
а	Items that will not be reclassified to profit or loss [net of tax]						
	Re-measurement loss on post employment defined benefit plans	-	(1)	(1)	(1)	(4)	
	Income tax effect on above items	-	-	-	-	1	
_	Total Other Comprehensive Income [net of tax]	-	(1)	(1)	(1)	(3)	
7	Total Comprehensive Income [5+6]	80	61	77	141	157	3
8	Paid-up equity share capital [Face Value ₹ 10/- each]	636	636	636	636	636	6
9	Reserve excluding Revaluation Reserve [i.e. Other equity]			¥1			39,7
10	Earnings per share [not annualised for the quarter]						
а	Basic [₹]	1.26	0.97	1.23	2.23	2.51	5.
b	Diluted [₹]	1.26	0.97	1.23	2.23	2.51	5.

Notes :

1. The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on November 11, 2024. The Statutory Auditors have carried out Limited Review of the aforesaid results. 2. The Company operates in one segment, namely "Consumer Products".

After the end of the reporting period, on October 30, 2024, the Company entered into Share Purchase Agreement("SPA") with the Promoters and other Shareholders ("the sellers") of 3. Naturel (India) Private Limited ("NIPL"), for acquisition of the entire share capital of NIPL. NIPL is a leading healthy snacking company engaged in the business of manufacturing, research and development, marketing and selling of Nutrition bars, Protein cookies, Protein Chips and health food products under brands – Ritebite Max Protein (Protein fueled healthy snacks) and Ritebite (fiber-enriched snacks). The cost of acquisition is ₹ 3900 Million which comprises of upfront consideration of ₹ 3690 Million and earnout consideration of ₹ 210 Million, which shall be determined upon achievement of agreed milestone for the financial year 2024-25. This acquisition is expected to be completed within a period of sixty days from the date of execution of SPA.

4. Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

, · · × , ×					
		4			
s					
				· · · · · · · · · · · · · · · · · · ·	
	Standalone Statement of Asse	ets and Liabilities	<u> </u>	₹ in Mi	
				As a	
Particulars			1 1 7 1 1 1	September	March
				30, 2024	31, 2024
POPTO-				[Unaudited]	[Audited]
ASSETS: Non-current assets:					ļ
Property, plant and equipment				304	313
Capital work-in-progress		•		52	40
Goodwill				228	228
Financial assets:					J
Investments				36,713	36,713
Loans				2,117	2,125
Other financial assets				4	4
Deferred tax asset [net]				313	359
Other non-current assets				38	2
Assets for tax [net]				31	56
Total Non-Current Assets				39,800	39,840
Current assets:				1	
Inventories				116	101
Financial assets:					
Investment		L		579	48
Trade receivables				156	78
Cash and cash equivalents				13	92
Bank balance other than cash and cash equivalents	<i>6</i>			4	4
Loans				42	698
Other current financial assets				113	101
Other current assets				175	196
Total Current Assets				1,198	1,318
Total Assets				40,998	41,158
EQUITY AND LIABILITIES:					
EQUITY:					
Equity share capital				636	636
Other equity				39,546	39,723
Total Equity				40,182	40,359
LIABILITIES:					
Non-current liabilities:					1
Financial liabilities:					1
Lease liabilities				5	6
Other financial liabilities				11	11
Provisions				36	32
Total Non-Current Liabilities				52	49
Current liabilities:					
Financial liabilities:				1	
Borrowings				500	500
Lease liabilities				2	1
Trade payables:					
Due to Micro and Small enterprises				15	14
Due to other than Micro and Small enterprises				185	179
Other financial liabilities				37	31
				11	12
Other current liabilities					10
Other current liabilities Provisions				14	13
Other current liabilities					13 750

Adjustments for: 1 Deprecision and anontisation expense 1 Net gain on sale of investments (2) Precision of investments (3) Interest expense, bank commission and charges 10 Interest expense, bank commission and charges 10 Prevision for employee benefits 12 Operating prefits 13 Prevision for employee benefits 13 Operating prefits expense, bank commission and charges 13 Interest expense bank instemption to a set and the set and th			
The Hellion The Hellion A Cash flow from operating addivides: Subjective Subjective <th>х х</th> <th></th> <th></th>	х х		
Particulars in the receive in the second sec	Unaudited Standalone Statement of Cash Flows		s
Call of the of real potential particulation reprote Specific potential particulation reprote particulation reprot particulation reprote partin partit partin particulation reprote particulation reprote parti			
A Cash flow from operating activities: 30, 2024 30, 2024 Point further to: 189 2 Depresentation and montipation exprese 18 Depresentation and montipation exprese 13 The gain of indepoint of the service 13 The service in indepoint of the service 13 The service indepoint of the service 1	Particulars		
A Gash flow from operating activities: Adjuster to form Adjuster A			
Adjustments for: Dependentiation and manchanism expanses the gale on site of instruments the gale of the gale on site of instruments the gale of the gal			
Depreciation and amountation expresses 18 bits and on additionation of financial methods of the second of profit and loss		189	20
Net gain on sets of investments 03 Het gain on sole of investments 03 Expected oracle toxic toxic on index excluding (network) statement of profit and loss 13 Interest express, back commission and charges 13 Effect of frequency charge 134 Operating profit backs writing open charges 134 Operating to the instating 13 Operating to the instating activities 13 Functase of property, plant and calipment and other intangibles assets 136 Functase of property, plant and calipment and other intangibles assets 136 Functase of property, plant and calipment and other intangibles assets 135 Current Brownelly field (regument / brownell) 132 Cash down from financing activities 132 Cash down from injunkti		10	6
Met gain on disposed of Property, plant and equipment - Expected cerefit loss on task enclose like life - Indexet expects, back considers and drames 2 Effect of foreign exchange movement in kans 2 Provision for enclose benefits 2 Constraint of the southing exclusion and drames 134 Indexet expects 135 Operating portific 134 Increase in other asside 135 Increase in other asside 135 Increase in other asside 135 Increase in other asside 136 Increase in other asside 135 Increase in other asside 136 Increase in other asside 137		and the second se	
Expected craft loss on trade receivables (red) - (3) Itel agin on investment and activation measured at for value through statement of profit and loss (3) Integrate income (3) Iffect of foreign exchange investment in loss (3) Iffect of foreign exchange investment in loss (3) Iffect of foreign exchange investment in loss (3) Increase/Decrease in investments (3) Increase in the investment in investments (3) Increase in the investment in investments (3) <td></td> <td>- (2)</td> <td></td>		- (2)	
Interest looms, bank commission and charges Firstext deresine, bank commission and charges Adjustments for: Increase in their excivable Decrease in other assets Adjustments for: Increase in their excivable Increase Increase in their excivable Increase Increase in their excivable Increase In		-	
Interest expense, bank commission and charges 10 Effect of frequency bunk commission 2 Production for analyzes bunktion 134 Application of the machine bunktion 136 Application of the machine bunktion 136 Application of the machine bunktion 136 Decrease in total machine bunktion 136 Cash generated from operations 137 Cash generated from operations 136 Cash generated from operations 136 Cash generated from operations 137 Cash generated from from adjustent and other intergibles assets 138 Cash generate from from adjustent and other intergibles assets 130 Cash generate from from from from from from from from			
Effect of forsign exchange movement in loans 2 Provision for enclowed benefits 334 Decenting particle before working capital changes 739 Decenting particle before working capital changes 73 Decenting parting activities 72 D			(8
Provision for employee benefits 4 Adjustments for: 78 Increases in tank receivables 78 Dicrosses (Decrease) in the interstories 78 Increases (Decrease) in the interstories 78 Increase (Decrease) in the interstories			
Operating profit before working capital changes 134 3 Algustments for Increases (Decrease in trade resolutions Increases) (Decrease in trade resolutions 13 1 Cash generated from operating activities: 13 1 Cash generated from operating activities: 13 1 Purchase of property, plant and equipment and other intangibles assets (58) 1 Purchase of property, plant and equipment and other intangibles assets 152 1 Purchase of property, plant and equipment and other intangibles assets 152 1 Purchase of property, plant and equipment and other intangibles assets 152 1 Proceeds from investing activities: 152 1 Cash news from financing activities 152 1 Cash equivalents at the end of the period 152 1 Cash and schwappent / taken) 100 1 Dividend paid 121 1 Cash and cash equivalents at the end of the period 134 1 Cash and cash equivalents at the end of the period 13 1 Cash and cash equivalents at the end of the period 13 1 Cash and cash equivalents at the end of the period 13 1 Cash and cash equivalents at the end of the period 13 2 Cash and cash equivalents at			_
Increase in trade receivables Increase in trade receivables 17 Decrease in other assets 13 (13) (13) (14) (13) (15) (13) (16) 14 (17) 14 (18) 14 (18) 14 (18) 14 (18) 14 (18) 14 (18) 14 (18) 14 (18) 14 (18) 14 (18) 14 (18) 15 (18) 16 (18) 16 (18) 16 (18) 16 (18) 16 (18) 16 (18) 16 (18) 16 (18) 16 (18) 16 (18) 12 (20) 12 (21) 12 (22) 12 (24) 12 (25) 12 (24) 12 (25) 12 (24) 12 (25) 12 (24) 12 (25) 12 <			14
Decrease in other assets 15 [Increase](Decrease) in other fabilities 15 Increase](Decrease) in other fabilities 16 Scath prevention operations 18 Vector from operations 18 Scath from operations 18 Purchase of property, plant and equipment and other intangibles assets 15 Proceeds from asjet of Proceet, plant and equipment 15 Reapment of fail to subclaims 15 Cash from string activities: 15 Proceeds from injuid mutual funds [net) 152 Interest received 152 C. Sath from financing activities: 152 Cash from financing activities: 152 C. Cash frow from financing activities: 152 C. Cash frow from financing activities: 152 C. Cash frow from financing activities: 152 Cash and cash equivalents [A+B+C] 150 ash and cash equivalents [A+B+C] 150 ash and cash equivalents [A+B+C] 15 ash and cash equivalents [A+B+C] 15 ash and cash equivalents [A+B+C] 15 Cash and cash equivalents [A+B+C] <td< td=""><td>Adjustments for:</td><td></td><td></td></td<>	Adjustments for:		
Increase() Decrease in inventories (15) Increase() Corress() in trade payables 24 Cash generated from operations 24 Direct taxes poid (net of refunds) 24 Each orn on experting activities 96 Purchase of Property, plant and equipment and other intangibles assets (58) Purchase of Property, plant and equipment and other intangibles assets (21) Purchase of Property, plant and equipment and other intangibles assets (22) Investing activities (22) Loan divent to subsidiaries (23) Investing activities (22) Cash from liquid mutual funds (net) (13) Interest nectored (13) Interest nectored (13) Cash and cash equivalents (HeAPE) (13) Et cash troom liquid intuka funds (net) (13) Interest nectored (13)			(6
increase/[Decrease] in the Habilities 5 0 Cash generated from operating activities 24 1 Purctases of property, plant and equipment and other intangibles assets 65 0 Purctases of property, plant and equipment and other intangibles assets 65 0 Proceeds from sole of Proceity, plant and equipment and other intangibles assets 650 0 Proceeds from investing activities: 805 22 Cash question activities: 620 1 (cash from from functing activities: 630 22 Current Browning (inter - (repayment) / taken) 635 252 Current Browning (inter - (repayment) / taken) 63 1 It decrease in cash and cash equivalents [A+B+C] 630 1 Cash and cash equivalents [A+B+C] 30, 2024 30, 2023 Cash and cash equivalents [A+B+C] 30 2 Cash and cash equivalents [A+B+C] 30 2 Cash and cash equivalents [A+B+C] 30, 2024 30, 2023 Cash and cash equivalents [A+B+C] 30 2 Cash and cash equivalents [A+B+C] 30,			1
Increase (in trade payables (cash green and the quinners of the payables (cash green and the quinners of the payables (cash green and quinners) (cas			(3
Cash generated from operating activities 74 Direct tases paid [net of refunds] 98 etc ash from operating activities 98 3. Cash from oninvesting activities 805 Processes from investing activities 805 Loan diven to subsidiaries 152 Cash flows from financing activities 152 C. Cash flows from financing activities 152 C. Cash flows from financing activities 133 Gash acts explorations 134 Objected paid 132 Direct spaid 131 Direct spaid 132 Direct spaid 131 Direct spaid 132 Direct spaid 131 September 131 September 30, 2024 Sign and cash equivalents the period * 131 Cash and cash equivalents the period * 131 Cash and cash equivalents the period * 131 Cash and cash equivalents 131 Cash and cash eq			(5
set cash from operating activities 98 3. Cash from sive sting activities: 158 Purchase of property, later and equipment and other intangibles assets 28 Purchase of property, later and equipment and other intangibles assets 28 Purchase of property, later and equipment and other intangibles assets 28 Purchase of property, later and equipment and other intangibles assets 28 Purchase of property, later and equipment and other intangibles assets 28 Purchase of property, later and equipment and other intangibles assets 28 Purchase of property, later and equipment and other intangibles assets 28 Purchase of property, later and equipment and other intangibles assets 28 Purchase of property, later and equipment and other intangibles assets 28 Purchase of property, later and equipment and other intangibles assets 29 Interest received 3152 32 Cash flows from financing activities 31 31 Et cash fuse of and cash equivalents [A+B+C] 38 36 Sach and cash equivalents comprise of 71 31 Particulars 30, 2024 30, 2024 30, 2024 Supprember September September		122.222	. 6
3. Cash flows from investing activities: (58) (1) Purchase of property, plant and equipment and other intangibles assets (58) (2) Purchase of property, plant and equipment and other intangibles assets (68) (2) Loan other to subsidiaries (143) (6) Loan other to subsidiaries (143) (6) Loan other to subsidiaries (122) (2) Lear other to subsidiaries (123) (13) Lear other to subsidiaries (122) (2) Cash flows from financing activities: (13) (13) Cash not confinancing activities (13) (13) Cash not confinancing activities (13) (13) Let decrease in cash and cash equivalents (2, 4, 4, 6) (29) (11) Let decrease in cash and cash equivalents at the beginning of the period (29) (11) ash and cash equivalents at the beginning of the period (20) (20) (21) Cash and cash equivalents (20, 2024) (30, 2024) (30, 2024) Subtidiane of the period * (21) (21) (21) (21) Let decrease in cash and cash equivalents (13) <td< td=""><td></td><td></td><td></td></td<>			
Purchase of property, plant and equipment and other intangibles assets Proceeds from sile of froquery, plant and equipment Repayment of loan by subsidiaries Loan alow to subsidiaries Loan alow to subsidiaries (143) (66) (1745) (143) (66) (1745) (143) (66) (143) (66) (144) (66) (143) (66) (144) (66) (143) (143) (146) (144) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (146) (146) (144) (146) (14	Net cash from operating activities	98	6
Purchase of property, plant and equipment and other intangibles assets Proceeds from sile of froquery, plant and equipment Repayment of loan by subsidiaries Loan alow to subsidiaries Loan alow to subsidiaries (143) (66) (1745) (143) (66) (1745) (143) (66) (143) (66) (144) (66) (143) (66) (144) (66) (143) (143) (146) (144) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (144) (146) (146) (146) (146) (144) (146) (14	3. Cash flows from investing activities:		
Response of foan by subsidiaries 6805 22 Loan qiven to subsidiaries (143) (6 [Investment in/) Proceeds from liquid mutual funds [net] 72 72 interest received 72 (3 et cash flows from financing activities: 152 (3 . Current Bornowing [net - (repayment) / taken] (13) (13) Repayment of least babilities (13) (13) Interest received (13) (13) (13) Statistics (13) (13) (13) (13) Interest paid (14) (16) (13) (13) (13) ist and cash equivalents (A+B+C) (13) (17) (11)		(58)	(3
Lan quen to subsidiaries (143) (6) Investment In/ Proceeds from liquid mutual funds [net] (526) (72 Investment In/ Proceeds from liquid mutual funds (13) (6) 2. Cash flows from financing activities (10) (10) Current Borrowings [net - (repayment)/ taken] (10) (10) Repayment of lease liabilities (10) (10) Dividend paid (238) (23) et cash rom financing activities (239) (23) ash and cash equivalents [A+B+C] (239) (23) ash and cash equivalents (A+B+C] (29) (11) ash and cash equivalents (A+B+C] (29) (21) ash and cash equivalents (A+B+C] (30, 2024) (30, 2024) ash and cash equivalents of the period * (30, 2024) (30, 2024) ash and cash equivalents (1) (1) ash and cash equivalents (1) (1) ash and cash equivalents (1) (20) ast			1
Intrestretived (226) Intrestretived 152 22 (3) 25, Cash flows from financing activities: (10) Current Borrwings [net - (repayment) / taken] (3) Repayment of less labilities (3) Interstretion (3) Widend paid (3) Let cash I used in J/ from financing activities (3) State and cash equivalents [A+B+C] (3) Sash and cash equivalents at the beginning of the period 96 3ash and cash equivalents at the end of the period * 12 Cash and cash equivalents at the end of the period * 13 Cash and cash equivalents at the end of the period * 13 Cash and cash equivalents at the end of the period * 13 Cash and cash equivalents at the end of the period * 13 Cash and cash equivalents at the end of the period * 13 Cash and cash equivalents at the end of the period * 13 Cash and cash equivalents 13 Interstructures 13 Cash and cash equivalents 13 Is at the date of the period * 12 Cash and cash equivalents 13 Is at the date of the period * 13 Cash and cash equivalents 13 Is at the date of the date of the period *			20
Interest received 72 iterash from / [used in] Investing activities 152 Cash flows from financing activities - Current Borrowings [net - (repayment) / taken] - Repayment of lease liabilities - Dividend paid (33) Let cash [numeric paid] (33) Dividend paid (33) Let cash quivalents the beginning of the period - Sash and cash equivalents the beginning of the period - Sash and cash equivalents the beginning of the period - Cash and cash equivalents the beginning of the period - Cash and cash equivalents the beginning of the period - September September			
Let cash from/ [used in] investing activities 152 (3) C. Cash flows from financing activities: (3) (3) Current Browings [net - (repayment) / taken] (3) (3) Repayment of less liabilities (3) (3) (3) Interest paid (3) (3) (3) (3) Dividend paid (3) <td></td> <td></td> <td>3</td>			3
Current Borrowings [net - (repayment) / taken] Repayment of lease liabilities Interest paid Dividend paid let cash [used in]/ from financing activities let decrease in cash and cash equivalents [A+B+C] cash and cash equivalents at the end of the period * Cash and cash equivalents the end of the period * Cash and cash equivalents comprise of: Tarticulars Cash and cash equivalents and cash equivalents Cash and cash equivalents and liquid mutual funds: Cash and cash equivalents (as above) Cash and cash equivalents (by Order of the Boar For Zydus Wellness Limite For Zydus Wellness Limite Cash and Cash equivalents (by Criter of the Boar For Zydus Wellness Limite Cash and Cash equivalents (by Criter of the Boar For Zydus Wellness Limite Cash and Cash equivalents (by Criter of the Boar For Zydus Wellness Limite Cash and Cash equivalents (by Criter of the Boar For Zydus Wellness Limite Cash and Cash e			. (34
Current Borrowings [net - (repayment) / taken] Repayment of lease liabilities Interest paid Dividend paid let cash [used in]/ from financing activities let decrease in cash and cash equivalents [A+B+C] cash and cash equivalents at the end of the period * Cash and cash equivalents the end of the period * Cash and cash equivalents comprise of: Tarticulars Cash and cash equivalents and cash equivalents Cash and cash equivalents and liquid mutual funds: Cash and cash equivalents (as above) Cash and cash equivalents (by Order of the Boar For Zydus Wellness Limite For Zydus Wellness Limite Cash and Cash equivalents (by Criter of the Boar For Zydus Wellness Limite Cash and Cash equivalents (by Criter of the Boar For Zydus Wellness Limite Cash and Cash equivalents (by Criter of the Boar For Zydus Wellness Limite Cash and Cash equivalents (by Criter of the Boar For Zydus Wellness Limite Cash and Cash e			
Repayment of less itabilities (1) Interest paid (318) Dividend paid (329) Let cash [used in]/ from financing activities (329) Let decrease in cash and cash equivalents [A+B+C] (79) Cash and cash equivalents at the end of the period * (79) Cash and cash equivalents at the end of the period * 17 Cash and cash equivalents comprise of: ************************************			
Interest paid Dividend paid (10) (318) (329 11 (32) 11 (32) 11 (32 11 (32) 11		(1)	50
let cash [used in]/ from financing activities (329) 1 let decrease in cash and cash equivalents [A+B+C] (79) (11) cash and cash equivalents at the beginning of the period * 96 11 cash and cash equivalents at the end of the period * 96 11 cash and cash equivalents comprise of: ************************************			(
ket decrease in cash and cash equivalents [A+B+C] (729) (11) cash and cash equivalents at the beginning of the period * 96 11 Cash and cash equivalents at the end of the period * 17 2 Cash and cash equivalents comprise of: * * * Particulars September September September 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2023 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2024 30, 2023 30, 2024 30, 2024 30, 2023 30, 2024 30, 2024 30, 2024 30, 2023 30, 2024 <			(31
Sash and cash equivalents at the beginning of the period * 96 11 Cash and cash equivalents at the end of the period * 17 17 Cash and cash equivalents comprise of: ************************************	let cash [used in]/ from financing activities	(329)	17
Sash and cash equivalents at the beginning of the period * 96 11 Cash and cash equivalents at the end of the period * 17 17 Cash and cash equivalents comprise of: ************************************	lat decrease in cash and cash equivalents [A+B+C]	(70)	/11
Cash and cash equivalents at the end of the period * 17 3 Cash and cash equivalents comprise of: Imillion Particulars As at September September Imilion As at September September Imilion Imilion As at Imilion September September Imilion Imilion Imilion Imilion<			15
Particulars Particulars Image: september description of the Board of the Boa	Cash and cash equivalents at the end of the period *	17	3
Particulars Particulars Image: september description of the Board of the Boa	Cash and cash equivalents comprise of:		•
September September September 30, 2024 30, 2023 . Eank balance other than cash and cash equivalents 4 . Total 17 dditional Information: 4 ummary of Cash and cash equivalents and liquid mutual funds: 4 'articulars As at 'articulars September . Cash and cash equivalents (as above) 17 . Cash and cash equivalents (as above) 17 . Investment in liquid mutual funds 579 . Total 596 . Total 596 . Dr. Starvil P. Patu Dr. Sharvil P. Patu			
. Cash and cash equivalents 30, 2024 30, 2023 . Bank balance other than cash and cash equivalents 13 3 . Total 17 3 dditional Information: ummary of Cash and cash equivalents and liquid mutual funds: Image: Cash and cash equivalents and liquid mutual funds: rarticulars September September . Cash and cash equivalents (as above) 30, 2024 30, 2024 . Investment in liquid mutual funds 579 19 . Total 596 23 By Order of the Boar By Order of the Boar For Zydus Wellness Limite By Order of the Boar Dr. Sharvil P. Patu Dr. Sharvil P. Patu	articulars		
Cash and cash equivalents 13 3 Bank balance other than cash and cash equivalents 17 3 dditional Information: ummary of Cash and cash equivalents and liquid mutual funds: Image: Cash and cash equivalents and liquid mutual funds: Image: Cash and cash equivalents and liquid mutual funds: Particulars Image: Cash and cash equivalents (as above) September September 30, 2024 30, 2023 Investment in liquid mutual funds 579 19 19 3 Investment in liquid mutual funds 579 19 19 Investment in liquid mutual funds 596 23 By Order of the Board For Zydus Wellness Limite Image: Cash and Cash equivalents for Zydus Wellness Limite Investment in liquid mutual funds Image: Cash and Cash equivalents for Zydus Wellness Limite Image: Cash and Cash equivalents for Zydus Wellness Limite			
. Total 17 3 dditional Information: ummary of Cash and cash equivalents and liquid mutual funds: K in Million As at September September 30, 2024 30, 2023 30, 2024 30, 2023 17 3 Investment in liquid mutual funds 596 23 Investment in liquid mutual funds 596 23 Investment in liquid mutual funds 596 23 By Order of the Boarn For Zydus Wellness Limite By Order of the Boarn For Zydus Wellness Limite Dr. Sharvil P. Pate			3
dditional Information: <u>ummary of Cash and cash equivalents and liquid mutual funds:</u> tarticulars Image: Cash and cash equivalents (as above) 17 30, 2023 . Cash and cash equivalents (as above) 17 3 . Investment in liquid mutual funds 579 19 . Total 596 23 By Order of the Board For Zydus Wellness Limite For Zydus Wellness Limite . Total Dr. Sharvil P. Pate			
ummary of Cash and cash equivalents and liquid mutual funds: Iarticulars	. 10731	17	3
Particulars In Million September September 30, 2024 30, 2023 . Cash and cash equivalents (as above) 17 . Investment in liquid mutual funds 579 . Total 596 By Order of the Board For Zydus Wellness Limite For Zydus Wellness Limite Dr. Sharvil P. Pate			
As at September 30, 2024 30, 2023 30, 2024 30, 2023 30, 2024 30, 2023 30, 2024 30, 2023 30, 2024 30, 2023 30, 2024 30, 2023 30, 2024 30, 2023 30, 2024 30, 2024 30, 2023 30, 2024 30, 2023 30, 2024 30, 2024 30, 2024 30, 2023 30, 2024 30, 2024	ummary of Cash and cash equivalents and liquid mutual funds:	₹ in Mi	Ilion
September September September 30, 2024 30, 2023 . Cash and cash equivalents (as above) 17 3 . Investment in liquid mutual funds 579 19 . Total 596 23 By Order of the Board For Zydus Wellness Limite For Zydus Wellness Limite Dr. Sharvil P. Patu			
. Cash and cash equivalents (as above) 17 3 . Investment in liquid mutual funds 579 19 . Total 596 23 By Order of the Board For Zydus Wellness Limite For Zydus Wellness Limite . Total Dr. Sharvil P. Pate	lasticulare		September
. Investment in liquid mutual funds . Total By Order of the Board For Zydus Wellness Limite Dr. Sharvil P. Pate	articulars		
. Total By Order of the Board For Zydus Wellness Limite Dr. Sharvil P. Pate	• • • • • •		
By Order of the Board For Zydus Wellness Limite AppAt Dr. Sharvil P. Pate	. Cash and cash equivalents (as above)	570	23
For Zydus Wellness Limite AppAA Dr. Sharvil P. Patu	. Cash and cash equivalents (as above) . Investment in liquid mutual funds		
Dr. Sharvil P. Pate	. Cash and cash equivalents (as above) . Investment in liquid mutual funds	596	af the D
Dr. Sharvil P. Pate	. Cash and cash equivalents (as above) . Investment in liquid mutual funds	596 By Orde	
Dr. Sharvil P. Pate	. Cash and cash equivalents (as above) . Investment in liquid mutual funds	596 By Orde	
Dr. Sharvil P. Pate	. Cash and cash equivalents (as above) . Investment in liquid mutual funds	596 By Orde	
Dr. Sharvil P. Pate	. Cash and cash equivalents (as above) . Investment in liquid mutual funds	596 By Orde	
	. Cash and cash equivalents (as above) . Investment in liquid mutual funds . Total	596 By Orde	
	. Cash and cash equivalents (as above) . Investment in liquid mutual funds . Total	596 By Orde	
	. Cash and cash equivalents (as above) . Investment in liquid mutual funds . Total	596 By Orde	
Chairma	. Cash and cash equivalents (as above) . Investment in liquid mutual funds . Total	596 By Orde For Zydus W	reliness Limiter

MUKESH M. SHAH & CO.

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

To,

The Board of Directors, Zydus Wellness Limited

- We have reviewed the accompanying statement of Consolidated unaudited financial results of Zydus Wellness Limited ['the Parent'] and its subsidiaries [the Parent and its subsidiaries together referred to as 'the Group'] for the quarter and half year ended on September 30, 2024 ['the Statement'] attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended ("the Listing Regulations").
- 2. This statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Listing Regulations, as amended, to the extent applicable.

- 4. The Statement includes the financial results of the following entities:
 - a) Parent Company
 - i) Zydus Wellness Limited
 - b) Subsidiary Companies
 - i) Zydus Wellness Products Limited
 - ii) Liva Nutritions Limited
 - iii) Liva Investments Limited
 - iv) Zydus Wellness International DMCC
 - v) Zydus Wellness (BD) Pvt Limited
- 5. Based on our review conducted and procedures performed as stated in Paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and





7th Floor, Heritage Chambers, Behind Bikanerwala Sweets, Near Azad Society, Nehru Nagar, Ahmedabad-380015

MUKESH M. SHAH & CO.

CHARTERED ACCOUNTANTS

Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of a subsidiary Company included in the consolidated unaudited financial results, whose interim financial information reflect [the figures reported below are before giving effect to consolidation adjustments] total assets of ₹ 31,527 million as at September 30, 2024, total income of ₹ 4,902 million and ₹ 13,243 million for the quarter and half year ended September 30, 2024 respectively, total net loss after tax of ₹ 818 million and ₹ 204 million for the quarter and half year ended September 30, 2024 respectively, total comprehensive income of ₹ (817) million and ₹ (202) million for the quarter and half year ended September 30, 2024 respectively and net cash outflows of ₹ 2,099 million for the half year ended September 30, 2024, as considered in the Statement. This interim financial information has been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated financial results also include the financial information of 2 subsidiary companies included in the consolidated unaudited financial results, whose interim financial information reflect [the figures reported below are before giving effect to consolidation adjustments] total assets of ₹ 399 million as at September 30, 2024, total income of ₹ 188 million and ₹ 366 million for the quarter and half year ended September 30, 2024 respectively, total net Loss after tax of ₹ 31 million and ₹ 68 million for the quarter and half year ended September 30, 2024 respectively, total comprehensive income of ₹ (31) million and ₹ (68) million for the quarter and half year ended September 30, 2024, as considered in the Statement. No limited review of this financial information has been carried out by the auditors of the subsidiary; however, according to the information and explanations given to us by the Management, these interim financial results/ information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information as certified by the management.

Annedabad-15

For Mukesh M. Shah & Co Chartered Accountants Firm Registration No. 106625W

Mukesh M. Shah Partner Membership No. 030190

Place: Ahmedabad Date: November 11, 2024 UDIN: <u>240301906KHR7G4028</u>

+91-79-26472000 | contact@mmsco.in | www.mmsco.in

^{7&}lt;sup>th</sup> Floor, Heritage Chambers, Behind Bikanerwala Sweets, Near Azad Society, Nehru Nagar, Ahmedabad-380015

Tude	Zydus We	Ilness Limited					
Zydu Wellna	Registered office : Zydus Corporate Park, Scheme No. 63, Cardbingers III			 Near Vaishnode 	vi Circle,		
vveline	ESS Sarkhej-Gandhinagar Hi Tel. No. (+91-79) 4804 0000 Website: www.			0401 0023400			
1	Statement of Consolidated Unaudited Financial Result				mber 30, 202	4	
			er und man jet		Aillion		
							1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
			Quarter Ended		Half Yea	ar Ended	Year Ende
Sr. No.	Particulars	September	June	September	September	September	March
NO.		30, 2024	30, 2024	30, 2023	30, 2024	30, 2023	31, 202
		[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Audited
1 1	Income						
a	Revenue from operations						
i	Sales	4,907	8,391	4,379	13,298	11,371	23,
ii	Other operating income	22	19	20	41	49	
	Total Revenue from operations	4,929	8,410	4,399	13,339	11,420	23,
b	Other income	40	50	41	90	65	
	Total Income	4,969	8,460	4,440	13,429	11,485	23,
	Expenses	2,068	2 576	1.015		4547	
а	Cost of materials consumed	133	2,576 548	1,815 137	4,644 681	4,517 495	10
b	Purchases of stock-in-trade Changes in inventories of finished goods, work-in-progress and stock-in-trade	374	548 609	460	983	730	1,
C		522	594	483	1,116	956	1
d e	Employee benefits expense Finance costs	9	36	65	45	116	-
f	Depreciation and amortisation expense	49	51	58	100	120	
g	Advertisement and promotion expense	634	1,243	507	1,877	1,551	2
h	Other expenses	1,002	1,288	831	2,290	1,840	3
	Net [gain] on foreign currency transactions	2,002	(1)	(2)	(1)	(2)	5
· -	Total Expenses	4,791	6,944	4,354	11,735	10,323	20
	Profit before exceptional items and tax [1-2]	178	1,516	86	1,694	1,162	20
	Exceptional items [net] [Refer Note 4]	(59)	-	-	(59)	142	~
	Profit before tax [3-4]	237	1,516	86	1,753	1,020	2
	Tax expense		-,			-/	-
a	Current tax	-	1		1	(2)	
b	Deferred tax [Refer Note 5]	28	38	27	66	(141)	
7	Total tax expense	28	39	27	67	(143)	
7 1	Net Profit [5-6]	209	1,477	59	1,686	1,163	2
8 0	Other Comprehensive Income [OCI]			*			
a I	Items that will not be reclassified to profit or loss [net of tax]						
	Re-measurement loss on post employment defined benefit plans	. 1	1		2	(1)	
	Income tax effect on above items	-	(1)	-	(1)		
	Total	1	-	-	1	(1)	
bI	Items that will be reclassified to profit or loss						
	Exchange differences on transaction of financial statement of a foreign operations	-	(1)	(1)	(1)	(1)	
	Total		(1)	(1)	(1)	(1)	
	Total Other Comprehensive Income [net of tax]	1	(1)	(1)	-	(2)	2
	Total Comprehensive Income [7+8]	210	1,476	58	1,686	1,161	2,
	Total Comprehensive Income attributable to:	210	1,476	58	1 606	1 161	-
a	Owners of the Parent Paid-up equity share capital [Face Value ₹ 10/- each]	636	636	636	1,686 636	1,161	2
	Reserve excluding Revaluation Reserve [i.e. Other equity]	030	030	030	030	636	53
	Earnings per share [not annualised for the quarter]						52,
13 E	Basic [*]	3.28	23.21	0.93	26.50	18.28	4
b	Diluted [₹]	3.28	23.21	0.93	26.50	18.28	4
tes :	bove financial results were reviewed by the Audit Committee and then approved by the d Review of the aforesaid results.						
Limited				warters of the fier	ancial year. Hence	the performance	of these au
Limited 2. The Gr 3. Due to is not r	roup operates in one segment, namely "Consumer Products". s seasonality of some of the Group's products, Group's Revenues and Group's Profits are sl representative and cannot be generalised for other quarters. tional items comprise:	kewed in favour of	the first and last o		ficial year. Hence		or these qu
Limited 2. The Gr 3. Due to is not r	o seasonality of some of the Group's products, Group's Revenues and Group's Profits are sl	kewed in favour of		tin M	lillion	-	
Limited 2. The Gr 3. Due to is not r 4. Excepti	o seasonality of some of the Group's products, Group's Revenues and Group's Profits are sl representative and cannot be generalised for other quarters.	sewed in favour of	the first and last of Quarter Ended June			-	Year End March

Sr.			Quarter Endeu		Hall fear Endeu		Year Ended	
No.	Particulars	September	June	September	September	September	March	
140.		30, 2024	30, 2024	30, 2023	30, 2024	30, 2023	31, 2024	
		[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Audited]	
i.	As a part of manufacturing and supply chain network optimisation and to make	-	a	-	16 (-	177	177	
	manufacturing operations leaner and agile to the consumer needs, the Group had							
	conducted a strategic review of its manufacturing footprint. In view of the same, the Board							
	of Directors of Zydus Wellness Product Limited (ZWPL), a wholly owned subsidiary Company							
	of the Group, at their meeting held on June 17, 2022, passed a resolution to cease the							
	operations of Sitarganj manufacturing facility. The expenses incurred so far in connection							
	with the cessation of Sitarganj facility have been classified as Exceptional items							
ii.	ZWPL has sold its assets located at Rabale, Mumbai which were classified as "Assets held	-	-	-	-	(35)	(35)	
	for sale" from Property, Plant and Equipment in the previous financial year (as per Ind AS							
	105), the corresponding gain have been recognized as Exceptional items	((==)			
10.	ZWPL has sold the "Equals Two" brand including its trademark to Zydus Lifesciences Limited	(59)	-	-	(59)	-	-	
	("The Parent Company") and recorded the profit as an exceptional item							
Tot	al	(59)	-	-	(59)	142	142	

 Total
 (59)
 (59)
 142
 142

 5. Deferred tax expense for the half year ended September 30, 2023 and full year ended March 31,2024 includes recognition of Minimum Alternate Tax (MAT) credit entitlement amounting to ₹ 188 Million.
 6. After the end of the reporting period, on October 30, 2024, the Company entered into Share Purchase Agreement("SPA") with the Promoters and other Shareholders ("the sellers") of Naturell (India) Private Limited ("NIPL"), for acquisition of the entire share capital of NIPL. NIPL is a leading healthy snacking company engaged in the business of manufacturing, research and development, marketing and selling of Nutrition bars, Protein Cokies, Protein Chips and health food products under brands – Ritebite Max Protein (Protein fueled healthy snacks) and Ritebite (fiber-enriched snacks). The cost of acquisition is ₹ 3900 Million which comprises of upfront consideration of ₹ 3690 Million and earnout consideration of ₹ 210 Million, which shall be determined upon achievement of agreed milestone for the fore service in the promoterial uner 2004 3E. The convertient of the providence of the the reporting of the the providence of the the providence of the the fore service of the top of the optic service of the top of the top of the top of the optic service of the top of the optic service of the top of the optic service of the top of the toptic service of the toptic

acquisition is 3 3900 Million which comprises or upfront consideration of 4 300 Million, which shall be determined upon achievement of agreed milestone for the financial year 2024-25. This acquisition is expected to be completed within a period of sixty days from the date of execution of SPA. 7. Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period. 8. The detailed standalone results are available on the Company's website: www.zyduswellness.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com]. The summarised standalone financial results of the Company are as below:

	₹ in					Million			
Sr.	9		Quarter Ended		Half Yea	Year Ended			
	Particulars	September	June	September	September	September	March		
No.		30, 2024	30, 2024	30, 2023	30, 2024	30, 2023	31, 2024		
		[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Audited]		
i.	Revenue from operations	633	634	578	1,267	1,179	2,448		
ii.	Profit before tax	105	84	104	189	208	448		
iii.	Profit after tax	80	62	78	142	160	337		
iv.	Other Comprehensive Income		(1)	(1)	(1)	(3)	. (3)		
v.	Total Comprehensive Income	80	61	77	141	157	: 334		

9	ø		
Consolidated Statement of Assets and Liabilities	J		
		₹ in M	
Particulars		As	at March
		30, 2024	31, 2024
ASSETS:		[Unaudited]	[Audited
Non-current assets:		2 424	2.
Property, plant and equipment Capital work-in-progress		2,424 167	2,4
Goodwill		39,200	39,2
Other intangible assets		5,403	5,4
Financial assets: Investment		7	
Other financial assets		38	
Deferred tax asset [net]		1,496	1,5
Other non-current assets Assets for tax [net]		176 64	1
Total Non-Current Assets		48,975	48,9
Current assets: Inventories		3,509	4,6
Financial assets:			
Investment		3,665	7
Trade receivables Cash and cash equivalents		2,102 206	2,8
Bank balance other than cash and cash equivalents		8	1,5
Loans		14	-
Other current financial assets Other current assets		249 990	3
Total Current Assets		10,743	12,14
Assets classified as held for sale		357 60,075	<u> </u>
Total Assets		00,075	01,4
EQUITY AND LIABILITIES:			
EQUITY: Equity share capital		636	6
Other equity		54,307	52,9
Total Equity		54,943	53,5
LIABILITIES:			
Non-current liabilities: Financial liabilities:	*		
Lease liabilities		23	1
Other financial liabilities		20	
Provisions Other Non Current Liabilities		173	. 19
Total Non-Current Liabilities		222	2
Current liabilities:			
Financial liabilities: Borrowings		1,500	3,24
Lease liabilities		1,500	3,2
Trade payables:			
Due to Micro and Small enterprises Due to other than Micro and Small enterprises		121 2,515	3 3,3
Other financial liabilities		158	3,5
Other current liabilities		236	3
Provisions Total Current Liabilities		362 4,910	7,69
Total Equity and Liabilities		60,075	61,4

0 0		
	•	
Unaudited Consolidated Statement of Cash Flows	₹in M	lillion
Particulars	Half Yea	
	September 30, 2024	September 30, 2023
A. Cash flow from operating activities:		
Profit before tax Adjustments for:	1,753	1,020
Depreciation and amortisation expense	100	120
Net gain on disposal of property, plant and equipment and asset held for sale Expected credit loss on trade receivables [net]	(1)	(37)
Net gain on sale of investments	(33)	7 (13)
Net gain on investments mandatorily measured at fair value through statement of profit and loss	(27)	(2)
Interest income Interest expense, bank commission and charges	(27) 45	(47) 116
Effect of foreign exchange movement in loans	1	-
Amortisation of deferred revenue on Government grants Provision for employee benefits	(2) 21	(3)
Operating profit before working capital changes	1,830	1,167
Adjustments for: Decrease in trade receivables	736	798
Decrease/ [Increase] in other assets	202	(69)
Decrease in inventories Decrease in other liabilities	1,167 (31)	917 (286)
Decrease in trade payables	(980)	(1,147)
Cash generated from operations	2,924	1,380
Direct taxes paid [net of refunds] Net cash from operating activities	28	(12)
		2,000
B. Cash flows from investing activities: Purchase of property, plant and equipment and other intangibles assets	(101)	(120)
Proceeds from sale of property, plant and equipment and assets held for sale	(191) 6	(139) 19
[Investment in]/ Proceeds from liquid mutual funds [net]	(2,836)	73
Proceeds from non-current fixed deposit [net] Interest received	27	(1) 47
Net cash used in investing activities	(2,994)	(1)
C. Cash Reve from Francisc activities		
C. Cash flows from financing activities: Repayment of non-current borrowings	·	(625)
Current Borrowings [net - (repayment) / taken] Repayment of lease liabilities	(1,740)	1,180
Interest paid	(9)	(8) (77)
Dividend paid Net cash [used in]/ from financing activities	(318)	(319) 151
	(2,139)	151
Net [decrease]/ increase in cash and cash equivalents [A+B+C] Cash and cash equivalents at the beginning of the period	(2,181) 2,395	1,518 381
Cash and cash equivalents at the end of the period *	214	1,899
*Cash and cash equivalents comprise of:		
	₹ in M	
Particulars	September	September
	30, 2024	30, 2023
a. Cash and cash equivalents b. Bank balance other than cash and cash equivalents	206 8	353 1,546
c. Total	214	1,899
Additional Information:		
Summary of Cash and cash equivalents, liquid mutual funds and fixed deposits more than twelve months:	₹ in Mi	llion
Particulars	Asi	at
	September 30, 2024	September 30, 2023
a. Cash and cash equivalents (as above)	214	1,899
b. Investment in liquid mutual funds c. Fixed deposits more than twelve months	3,665	. 642 5
d. Total	3,879	2,546
	By Orde	er of the Board,
		ellness Limited,
*	\cap	
	N/	0 0
	X.	-t- I
	12h	
	11	
	Dr.	Sharvil P. Patel
Place: Ahmedabad Date: November 11, 2024	1	Chairman DIN: 00131995